ArticleActa dermato-venereologica2026
Comparison of the Burden of Acne Vulgaris in China vs Globally: Insights from the Global Burden of Disease Study (2021) and Projections to 2050.
Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient Expectations, Safety Concerns, and Adherence to Topical Acne Medications: Findings from a Web-Based Survey.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne vulgaris (AV) poses a significant health challenge in China, adversely affecting patients' quality of life and mental health. Updated evidence on acne burden in China integrating temporal trends, China-global comparisons, change-point patterns, and future projections remains limited. This study aimed to provide an updated assessment of AVacne vulgaris burden in China, including temporal trends and future projections, and to clarify its public health implications. Using data from the 2021 Global Burden of Disease (GBD) study, estimated annual percentage changes (EAPCs) for AVacne vulgaris were calculated for China and globally, while change-point patterns were assessed using joinpoint regression. An age-period-cohort (APC) analysis was subsequently performed, followed by Bayesian age-period-cohort (BAPC) projection of China's AVacne vulgaris burden to 2050. From 1990 to 2021, the prevalence, incidence, and disability-adjusted life years (DALYs) associated with AVacne vulgaris in China exhibited sustained increases, outpacing global rates. APCAge-period-cohort analysis revealed a peak incidence at ages 10-14 years. Overall, the main burden was concentrated in adolescence. BAPCBayesian age-period-cohort projections indicated that China's AVacne vulgaris burden will continue to rise from 2022 to 2050,, with a disproportionately greater impact on females. These findings support prioritising evidence-based prevention, early recognition, and management strategies for adolescents and for females in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.